Ovatech Reports Successful Completion of Phase 2 Clinical Trial of Ovaprene(TM) Non-Hormonal Intravaginal Contraceptive Ring

AUBURNDALE, Mass.--(BUSINESS WIRE)--Ovatech, an emerging women’s health-focused company, announced today that the Company’s Phase 2 clinical study of its non-hormonal, intravaginal contraceptive ring, Ovaprene, has been successfully completed. Ovaprene is a ‘one-size-fits-all’ patented, female-controlled, intravaginal organic silicone ring barrier-contraceptive that is designed to continuously release spermiostatic and spermicidal non-drug agents over a four-week period.
MORE ON THIS TOPIC